Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
about
Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patientsSuccessful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.Niemann-Pick type C: focus on the adolescent/adult onset form.Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.Miglustat in Niemann-Pick disease type C patients: a review
P2860
Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Results from a 9-year Intensiv ...... Zavesca(®) )-treated patients.
@en
type
label
Results from a 9-year Intensiv ...... Zavesca(®) )-treated patients.
@en
prefLabel
Results from a 9-year Intensiv ...... Zavesca(®) )-treated patients.
@en
P2093
P2860
P356
P1476
Results from a 9-year Intensiv ...... Zavesca(®) )-treated patients.
@en
P2093
Audrey Muller
Bruno Bembi
Ivo N van Schaik
Jonathan Alsop
Monika Brand
P2860
P304
P356
10.1002/PDS.3760
P577
2015-02-05T00:00:00Z